Following approval by the National Health Surveillance Agency (Anvisa), Brazil became the first country to launch a single-dose tetravalent dengue vaccine. Developed by the Butantan Institute in partnership with the US National Institutes of Health (NIH), the vaccine (Butantan-DV) protects against all four serotypes of the virus.
Previously, Brazil's public health system (SUS) relied on the Japanese-manufactured vaccine, Qdenga, which requires a two-dose schedule spaced three months apart. Public health officials found that many individuals failed to return for their second dose, leaving them only partially protected.
A single-dose shot eliminates this barrier and is particularly revolutionary for hard-to-reach, isolated communities—such as indigenous populations in the Amazon—who no longer need to make repeated trips to medical centres.
Long-term Phase 3 clinical trial results published in Nature Medicine demonstrated that the vaccine offers durable, robust defence over a five-year monitoring period:
*Overall efficacy: 74% to 75% effective at preventing symptomatic dengue infections.
*Severe case reduction: 89% to 91% effective at reducing severe forms of the disease.
*Hospitalisation prevention: 100% effective—zero vaccinated participants in the five-year trial required hospitalisation for dengue.
Since vaccinating a country of continental dimensions is a massive logistical challenge, Brazil's Ministry of Health structured the rollout into highly calculated phases. The first phase would target pilot municipalities, while phase 2 would focus on protecting the frontline healthcare workers.
For your daily dose of medical news and updates, visit: HEALTH
To meet massive domestic demand and prepare for future international distribution to other heavily hit Latin American nations (like Peru, Colombia, and Argentina), scaling up production is the primary focus.
The Butantan dengue vaccine is said to be 81 per cent effective against hospitalisation for the mosquito-borne disease for at least five years.
The Brazilian Health Regulatory Agency approved Butantan-DV in November 2025 for use in people aged 12 to 59 years.
Over the past two decades, the spread of dengue has greatly increased globally.
Why is dengue fever is hard to beat with vaccines?
Dengue is not caused by just one virus, but by four closely related ones known as serotypes. When someone is infected with one, the immune system usually protects them against that specific type- but not against the other three.
According to experts, understanding the immune mechanisms is essential for designing safer and more effective vaccines. However, vaccine performance still varies depending on factors such as prior infection, age and transmission intensity.
Dengue spreads through the bite of infected Aedes mosquitoes. These mosquitoes breed in standing water, which is often near where people live.
What are the dengue symptoms?
The symptoms of dengue include: high fever, headache, pain behind the eyes, muscle and joint pain, nausea and rash.
Though most of them recover within about a week, in some cases the infection can become severe and lead to bleeding, organ damage or shock. Transmission tends to increase during rainy seasons, when mosquito populations expand.